Yet there is also evidence showing that in AD, the SV2A loss takes precedence in glutamatergic rather than GABAergic nerve terminals (Govindpani et al., 2017), and the specific regulatory mechanism of SV2A on APP remains to be elucidated. Here, SV2A is linked to Alzheimer disease.